Brochure
2 Jul 2026
CDMO Solutions_Lupin Manufacturing Solutions
PDF 9.5 MB
Lupin Manufacturing Solutions (LMS) delivers fully integrated as well as standalone CDMO solutions spanning the complete development value chain, from building blocks and intermediates to drug substance and drug product. We enable innovators and pharma partners with phase-appropriate development, robust scale-up, GMP manufacturing, analytical excellence, and global regulatory alignment. Our capabilities extend across small molecules, complex chemistries, peptides, ADCs and oncology programs, supported by advanced containment and quality systems. With end-to-end integration, strong technical expertise, and reliable supply continuity, LMS empowers faster, de-risked, and cost-efficient advancement from early development to market.
Content provided by our supplier
Lupin Limited
-
Country/Region:India
-
On CPHI since:2019
-
Certificates:4
-
Employees:5000+
Company types
Primary activities
Other Content from Lupin Limited (6)
-
News Lupin Manufacturing Solutions Unveils Dedicated Oncology Block at Vizag, India
Lupin Manufacturing Solutions (LMS), a wholly owned subsidiary of global pharma major Lupin Limited (Lupin), today announced the commissioning of its dedicated Oncology Block at its Vizag facility in India. The new high-containment unit significantly enhances LMS’s end-to-end Contract Development and Manufacturing capabilities for High Potent Active Pharmaceutical Ingredients. It will support clients across the oncology development lifecycle from preclinical research to commercial manufacturing, addressing growing global demand for oncology drug development and manufacturing. -
Brochure HPAPI CDMO Services
At Lupin Manufacturing Solutions (LMS), we enable global pharmaceutical innovators to bring oncology therapies to market faster, safer and compliant. With deep scientific expertise, advanced containment infrastructure, and phase-appropriate manufacturing flexibility, we serve as an end-to-end CDMO partner for the development and production of highly potent oncology APIs and intermediates. Backed by the global legacy of Lupin Limited, our oncology operations combine scientific rigor, regulatory excellence, and scalable manufacturing from lab to commercial scale. -
News Lupin Manufacturing Solutions and PolyPeptide Announce Strategic Alliance to Scale Global Peptide Supply Chain
Lupin Manufacturing Solutions (LMS), a subsidiary of global pharma major Lupin Limited (Lupin), today announced a long-term strategic alliance with PolyPeptide Group AG (PolyPeptide) (SIX: PPGN), a specialized, global CDMO for peptide-based active pharmaceutical ingredients. This collaboration aims to enhance supply chain resilience, improve operational efficiency, and accelerate readiness for the rapidly expanding global peptides market. It also advances next-generation peptide therapeutics, including those for metabolics, supporting the long-term strategic growth of both organizations. -
Brochure Peptide Building Blocks
Every coupling reaction, purification cycle, and scale-up milestone depends on the integrity of the starting amino acids. At Lupin Manufacturing Solutions (LMS) Fmoc-protected amino acids are developed & manufactured to deliver:1. Consistent Coupling Performance
2. Controlled stereo-chemical integrity
3. Low impurity burden
4. Cleaner crude peptide profiles
5. Reduced downstream purification effort -
News Lupin Manufacturing Solutions Announces Expansion of Manufacturing Facility at Dabhasa, India
Lupin Manufacturing Solutions (LMS), a global CRDMO and subsidiary of global pharma major Lupin Limited (Lupin), today announced a strategic expansion of its Dabhasa manufacturing facility, marking a significant step toward scaling its peptide building-blocks platform and CRDMO capabilities. -
Brochure API Product Portfolio
At Lupin Manufacturing Solutions, we recognize that generic APIs form the foundation of global healthcare access. Backed by more than five decades of Lupin’s pharmaceutical legacy, our generic API portfolio is designed to meet the highest standards of quality, scalability, and compliance ensuring that essential medicines remain accessible to patients worldwide. Our portfolio spans multiple therapeutic categories, including cardiovascular, central nervous system, respiratory, anti-infective, metabolic disorders, and oncology. Each API is developed and manufactured in USFDA-approved facilities, with regulatory documentation (DMFs, CEPs, dossiers) to support smooth global submissions.